Drugs / Pro-Vantage
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02709330 | Apr 2016 → Sep 2017 | amyotrophic lateral sclerosis | Richard Bedlack, M.D., Ph.D. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pro-Vantage | “* Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids'” NCT02709330 ↗ |